Briacell Therapeutics Corp (BCTX)

$3.69 +0.05 (1.23%)
Market Cap 32.45M
Revenue (ttm) 0.00
Net Income (ttm) -26.31M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 32,593
Avg Vol 228,436
Day's Range N/A - N/A
Shares Out 8.70M
Stochastic %K 38%
Beta 1.15
Analysts Strong Buy
Price Target $40.00

Company Profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agree...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 921 1810
Fax: 604 921 1898
Address:
Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada
Ashton_Karterson
Ashton_Karterson Jul. 21 at 6:33 PM
$SSM $CDT $EDBL $BCTX $TGL headquarters
0 · Reply
SmallCapVoice
SmallCapVoice Jul. 21 at 2:27 PM
What could be the next revolution in cancer treatment? $BCTX CEO Dr. William Williams joined the Progress, Potential, and Possibilities podcast to discuss the future of personalized cancer immunotherapy and BriaCell's approach to developing accessible, off the shelf treatments. Watch here: https://www.youtube.com/watch?v=zAGL5Wg0PYs
1 · Reply
BHWinehouse
BHWinehouse Jul. 21 at 1:12 PM
$BCTX Riddle me this Batman: MAYBE we'll see an enhanced collaboration (or?) with $INCY? We have been using their PD-1 inhibitor retifanlimab in our trial AND Williams just happened to have served as Vice President of Exploratory Development for them. They've stayed with us for 7 years so far, being quietly updated along the way. Maybe, maybe not. Something to think about while we wait.
1 · Reply
superguild
superguild Jul. 21 at 1:37 AM
$BCTX typical. Churn the price down then up to a lower high then down again. On and on it goes.
1 · Reply
SmallCapVoice
SmallCapVoice Jul. 20 at 5:59 PM
Worth watching: $BCTX entered into a manufacturing arrangement with FUJIFILM Biotechnologies California. Keep an eye on this one. https://www.contractpharma.com/breaking-news/briacell-taps-fujifilm-for-bria-imt-manufacturing/
0 · Reply
ZacksResearch
ZacksResearch Jul. 20 at 5:06 PM
$BCTX just hit a key milestone in its Phase 3 program 🚀 BriaCell expanded its pivotal Phase 3 metastatic breast cancer study into Canada with Sunnybrook’s Odette Cancer Centre joining the trial. ✅ First Canadian clinical site now active 🌎 More than 80 active U.S. clinical sites across 15 states 🎯 Phase 3 study is evaluating Bria-IMT plus an immune checkpoint inhibitor, with overall survival as the primary endpoint Learn what today’s news means for BCTX investors 👉 https://www.zacks.com/stock/quote/BCTX/detailed-earning-estimates?cid=sm-stocktwits-0-price_target-oc-38879&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_38879
0 · Reply
JediGreen
JediGreen Jul. 19 at 6:27 AM
$BCTX https://youtube.com/watch?v=zAGL5Wg0PYs&si=ffxkbv_yttcuLazk
0 · Reply
Kings124566
Kings124566 Jul. 17 at 9:50 PM
$BCTX $BCTXL Ok, well, happy camping.
0 · Reply
EscapePlan
EscapePlan Jul. 17 at 5:18 PM
$BCTX no volume today... everyone just waiting... waiting... waiting...
1 · Reply
nik4
nik4 Jul. 17 at 12:31 PM
$BCTX Accelerated Enrollment: Opening international sites like Sunnybrook Toronto gives BriaCell broader access to patient populations to reach their ~404-patient target faster, pushing them closer to the 144-event milestone needed for interim data readout.
0 · Reply
Latest News on BCTX
BriaCell (BCTX) Expands Phase 3 Study with New Clinical Site

2026-07-16T13:27:49.000Z - 5 days ago

BriaCell (BCTX) Expands Phase 3 Study with New Clinical Site

BriaCell announces Odette Cancer Centre joins Bria-IMT trial

2026-07-16T11:40:48.000Z - 5 days ago

BriaCell announces Odette Cancer Centre joins Bria-IMT trial

BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer

Thu, 16 Jul 2026 07:30:00 -0400 - 5 days ago

BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer

BriaCell (BCTX) Partners with Fujifilm for Cell Therapy Manufacturing

2026-07-15T13:32:56.000Z - 6 days ago

BriaCell (BCTX) Partners with Fujifilm for Cell Therapy Manufacturing

BriaCell arranges scalable manufacturing with Fujifilm Biotechnologies

2026-07-15T12:10:22.000Z - 6 days ago

BriaCell arranges scalable manufacturing with Fujifilm Biotechnologies

BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™

Wed, 15 Jul 2026 07:30:00 -0400 - 6 days ago

BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™

BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™

Tue, 07 Jul 2026 07:30:00 -0400 - 14 days ago

BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™

BriaCell Partners With Uneedle To Support Scalable Microneedle Delivery Of Bria-IMT

2026-06-26T10:06:07.000Z - 25 days ago

BriaCell Partners With Uneedle To Support Scalable Microneedle Delivery Of Bria-IMT

BriaCell (BCTX) Partners with Uneedle for Microneedle Technology Development

2026-06-25T13:25:58.000Z - 26 days ago

BriaCell (BCTX) Partners with Uneedle for Microneedle Technology Development

BriaCell enters MoU with Uneedle for microneedle technology

2026-06-25T11:45:30.000Z - 26 days ago

BriaCell enters MoU with Uneedle for microneedle technology

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™

Thu, 25 Jun 2026 07:30:00 -0400 - 26 days ago

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™

BriaCell Therapeutics Announces Closing of Offering

Tue, 02 Jun 2026 16:05:00 -0400 - 6 weeks ago

BriaCell Therapeutics Announces Closing of Offering

BriaCell Presents Positive Clinical Data at ASCO 2026

Mon, 01 Jun 2026 07:30:00 -0400 - 7 weeks ago

BriaCell Presents Positive Clinical Data at ASCO 2026

BriaCell Therapeutics Announces Pricing of Offering

Sun, 31 May 2026 19:59:00 -0400 - 7 weeks ago

BriaCell Therapeutics Announces Pricing of Offering

BriaCell (BCTX) Receives Positive Update from Data Safety Monitoring Board

2026-05-26T14:43:01.000Z - 2 months ago

BriaCell (BCTX) Receives Positive Update from Data Safety Monitoring Board

BriaCell receives recommendation for DSMB for Phase 3 Bria-ABC study

2026-05-26T13:05:39.000Z - 2 months ago

BriaCell receives recommendation for DSMB for Phase 3 Bria-ABC study

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Tue, 26 May 2026 07:30:00 -0400 - 2 months ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

BriaCell (BCTX) Unveils Key Clinical Data at ASCO Annual Meeting 2026

2026-05-22T13:27:19.000Z - 2 months ago

BriaCell (BCTX) Unveils Key Clinical Data at ASCO Annual Meeting 2026

BriaCell announces data from Bria-IMT at ASCO 2026

2026-05-22T11:49:02.000Z - 2 months ago

BriaCell announces data from Bria-IMT at ASCO 2026

BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026

Fri, 22 May 2026 07:30:00 -0400 - 2 months ago

BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026

BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™

Fri, 15 May 2026 07:30:00 -0400 - 2 months ago

BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™

BriaCell (BCTX) Completes Manufacturing for New Prostate Cancer Treatment

2026-05-14T15:31:53.000Z - 2 months ago

BriaCell (BCTX) Completes Manufacturing for New Prostate Cancer Treatment

BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer

Thu, 14 May 2026 07:30:00 -0400 - 2 months ago

BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer

BriaCell (BCTX) Expands Clinical Trial Network for Advanced Breast Cancer Treatment

2026-05-13T16:39:28.000Z - 2 months ago

BriaCell (BCTX) Expands Clinical Trial Network for Advanced Breast Cancer Treatment

BriaCell adds Penn Medicine as Phase 3 breast cancer study site

2026-05-13T14:41:55.000Z - 2 months ago

BriaCell adds Penn Medicine as Phase 3 breast cancer study site

BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

Wed, 13 May 2026 07:30:00 -0400 - 2 months ago

BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients

Tue, 12 May 2026 07:30:00 -0400 - 2 months ago

BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients

BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

Thu, 07 May 2026 07:30:00 -0400 - 2 months ago

BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

BriaCell receives FDA clearance to initiate Bria-BRES+ trial

2026-05-07T04:03:56.000Z - 2 months ago

BriaCell receives FDA clearance to initiate Bria-BRES+ trial

BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer

Wed, 06 May 2026 07:30:00 -0400 - 2 months ago

BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer

BriaCell Announces Six Clinical Data Presentations at ASCO 2026

Mon, 27 Apr 2026 07:30:00 -0400 - 3 months ago

BriaCell Announces Six Clinical Data Presentations at ASCO 2026

BriaCell (BCTX) Showcases Promising Data at AACR Annual Meeting

2026-04-21T13:28:43.000Z - 3 months ago

BriaCell (BCTX) Showcases Promising Data at AACR Annual Meeting

BriaCell presents anti-cancer activity of Bria-OTS

2026-04-21T11:54:23.000Z - 3 months ago

BriaCell presents anti-cancer activity of Bria-OTS

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models

Tue, 21 Apr 2026 07:30:00 -0400 - 3 months ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models

BriaCell (BCTX) Showcases Positive Clinical Data at AACR Annual Meeting

2026-04-20T13:32:04.000Z - 3 months ago

BriaCell (BCTX) Showcases Positive Clinical Data at AACR Annual Meeting

BriaCell presents Phase 3 quality of life, Phase 2 biomarker data at AACR

2026-04-20T11:41:56.000Z - 3 months ago

BriaCell presents Phase 3 quality of life, Phase 2 biomarker data at AACR

BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting

Mon, 20 Apr 2026 07:30:00 -0400 - 3 months ago

BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting

BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License

Tue, 31 Mar 2026 16:05:00 -0400 - 3 months ago

BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License

BriaCell (BCTX) to Reveal Key Findings at 2026 AACR Annual Meeting

2026-03-18T13:30:56.000Z - 4 months ago

BriaCell (BCTX) to Reveal Key Findings at 2026 AACR Annual Meeting

BriaCell to present four posters at the 2026 AACR

2026-03-18T11:42:55.000Z - 4 months ago

BriaCell to present four posters at the 2026 AACR

BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference

Wed, 18 Mar 2026 07:30:00 -0400 - 4 months ago

BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

Tue, 10 Mar 2026 07:30:00 -0400 - 4 months ago

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

Thu, 05 Mar 2026 16:04:00 -0500 - 4 months ago

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

BriaCell (BCTX) Expands Biologic Cancer Treatments Through New Agreement

2026-02-18T22:51:30.000Z - 5 months ago

BriaCell (BCTX) Expands Biologic Cancer Treatments Through New Agreement

BriaPro to purchase BriaCell’s license to develop, commercialize sCD80

2026-02-18T22:35:25.000Z - 5 months ago

BriaPro to purchase BriaCell’s license to develop, commercialize sCD80

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

Wed, 18 Feb 2026 17:30:00 -0500 - 5 months ago

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

BriaCell receives positive recommendation from DSMB for Phase 3 Bria-ABC study

2026-02-17T12:40:59.000Z - 5 months ago

BriaCell receives positive recommendation from DSMB for Phase 3 Bria-ABC study

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Tue, 17 Feb 2026 07:30:00 -0500 - 5 months ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

BriaCell Therapeutics (BCTX) Shows Promising Results in Metastatic Breast Cancer Treatment

2026-01-28T13:30:56.000Z - 6 months ago

BriaCell Therapeutics (BCTX) Shows Promising Results in Metastatic Breast Cancer Treatment

BriaCell says patient images show regression, resolution of metastsized tumors

2026-01-28T12:40:40.000Z - 6 months ago

BriaCell says patient images show regression, resolution of metastsized tumors

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

Jan 28, 2026, 7:30 AM EST - 6 months ago

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

BriaCell extends 18-47 month survival in Phase 2 metastatic breast cancer

2026-01-27T12:41:04.000Z - 6 months ago

BriaCell extends 18-47 month survival in Phase 2 metastatic breast cancer

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

Jan 27, 2026, 7:30 AM EST - 6 months ago

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

BriaCell Therapeutics Announces Closing of US$30 million Public Offering

Jan 15, 2026, 4:05 PM EST - 6 months ago

BriaCell Therapeutics Announces Closing of US$30 million Public Offering

BriaCell Therapeutics Announces Pricing of $30 million Public Offering

Jan 13, 2026, 9:00 PM EST - 6 months ago

BriaCell Therapeutics Announces Pricing of $30 million Public Offering

BriaCell Therapeutics trading resumes

2026-01-13T14:41:11.000Z - 6 months ago

BriaCell Therapeutics trading resumes

BriaCell Therapeutics trading halted, volatility trading pause

2026-01-13T14:35:29.000Z - 6 months ago

BriaCell Therapeutics trading halted, volatility trading pause

BriaCell reports sustained complete resolution of lung metastasis in Bria-OTS

2026-01-13T12:35:49.000Z - 6 months ago

BriaCell reports sustained complete resolution of lung metastasis in Bria-OTS

BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient

Jan 13, 2026, 7:30 AM EST - 6 months ago

BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient

“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine

Dec 18, 2025, 7:30 AM EST - 7 months ago

“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine

BriaCell presents Phase 2, Phase 3 data on Bria-IMT at SABCS 2025

2025-12-10T12:41:29.000Z - 7 months ago

BriaCell presents Phase 2, Phase 3 data on Bria-IMT at SABCS 2025

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

Dec 10, 2025, 7:30 AM EST - 7 months ago

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

BriaCell announces Phase 3 patient enrollment on track for 1H26 data readout

2025-12-09T12:35:35.000Z - 8 months ago

BriaCell announces Phase 3 patient enrollment on track for 1H26 data readout

BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

Dec 9, 2025, 7:30 AM EST - 8 months ago

BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

Dec 2, 2025, 7:30 AM EST - 8 months ago

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

Nov 25, 2025, 7:30 AM EST - 8 months ago

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

Nov 20, 2025, 7:30 AM EST - 8 months ago

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

Nov 18, 2025, 7:30 AM EST - 8 months ago

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

Nov 7, 2025, 7:30 AM EST - 9 months ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

Nov 4, 2025, 7:30 AM EST - 9 months ago

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

Oct 21, 2025, 7:50 AM EDT - 9 months ago

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

Oct 21, 2025, 7:30 AM EDT - 9 months ago

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

Oct 20, 2025, 7:30 AM EDT - 9 months ago

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

Oct 13, 2025, 7:30 AM EDT - 10 months ago

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

Oct 3, 2025, 7:30 AM EDT - 10 months ago

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

BriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

Aug 26, 2025, 7:30 AM EDT - 11 months ago

BriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

Aug 25, 2025, 7:30 AM EDT - 11 months ago

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

BriaCell Announces Proposed Effective Date of Share Consolidation

Aug 21, 2025, 12:00 PM EDT - 11 months ago

BriaCell Announces Proposed Effective Date of Share Consolidation

BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

Aug 13, 2025, 7:30 AM EDT - 1 year ago

BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

Jul 31, 2025, 7:30 AM EDT - 1 year ago

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

Jul 30, 2025, 7:30 AM EDT - 1 year ago

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

BriaCell's Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

Jul 29, 2025, 7:30 AM EDT - 1 year ago

BriaCell's Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

Jul 25, 2025, 7:30 AM EDT - 1 year ago

BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

Ashton_Karterson
Ashton_Karterson Jul. 21 at 6:33 PM
$SSM $CDT $EDBL $BCTX $TGL headquarters
0 · Reply
SmallCapVoice
SmallCapVoice Jul. 21 at 2:27 PM
What could be the next revolution in cancer treatment? $BCTX CEO Dr. William Williams joined the Progress, Potential, and Possibilities podcast to discuss the future of personalized cancer immunotherapy and BriaCell's approach to developing accessible, off the shelf treatments. Watch here: https://www.youtube.com/watch?v=zAGL5Wg0PYs
1 · Reply
BHWinehouse
BHWinehouse Jul. 21 at 1:12 PM
$BCTX Riddle me this Batman: MAYBE we'll see an enhanced collaboration (or?) with $INCY? We have been using their PD-1 inhibitor retifanlimab in our trial AND Williams just happened to have served as Vice President of Exploratory Development for them. They've stayed with us for 7 years so far, being quietly updated along the way. Maybe, maybe not. Something to think about while we wait.
1 · Reply
superguild
superguild Jul. 21 at 1:37 AM
$BCTX typical. Churn the price down then up to a lower high then down again. On and on it goes.
1 · Reply
SmallCapVoice
SmallCapVoice Jul. 20 at 5:59 PM
Worth watching: $BCTX entered into a manufacturing arrangement with FUJIFILM Biotechnologies California. Keep an eye on this one. https://www.contractpharma.com/breaking-news/briacell-taps-fujifilm-for-bria-imt-manufacturing/
0 · Reply
ZacksResearch
ZacksResearch Jul. 20 at 5:06 PM
$BCTX just hit a key milestone in its Phase 3 program 🚀 BriaCell expanded its pivotal Phase 3 metastatic breast cancer study into Canada with Sunnybrook’s Odette Cancer Centre joining the trial. ✅ First Canadian clinical site now active 🌎 More than 80 active U.S. clinical sites across 15 states 🎯 Phase 3 study is evaluating Bria-IMT plus an immune checkpoint inhibitor, with overall survival as the primary endpoint Learn what today’s news means for BCTX investors 👉 https://www.zacks.com/stock/quote/BCTX/detailed-earning-estimates?cid=sm-stocktwits-0-price_target-oc-38879&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_38879
0 · Reply
JediGreen
JediGreen Jul. 19 at 6:27 AM
$BCTX https://youtube.com/watch?v=zAGL5Wg0PYs&si=ffxkbv_yttcuLazk
0 · Reply
Kings124566
Kings124566 Jul. 17 at 9:50 PM
$BCTX $BCTXL Ok, well, happy camping.
0 · Reply
EscapePlan
EscapePlan Jul. 17 at 5:18 PM
$BCTX no volume today... everyone just waiting... waiting... waiting...
1 · Reply
nik4
nik4 Jul. 17 at 12:31 PM
$BCTX Accelerated Enrollment: Opening international sites like Sunnybrook Toronto gives BriaCell broader access to patient populations to reach their ~404-patient target faster, pushing them closer to the 144-event milestone needed for interim data readout.
0 · Reply
nik4
nik4 Jul. 17 at 12:26 PM
$BCTX Core Trial Design ParametersTarget Enrollment: Designed to enroll approximately 404 patients (surpassing 230 active enrollments as of mid-2026).
0 · Reply
BHWinehouse
BHWinehouse Jul. 17 at 12:02 PM
$BCTX BRIA-IMT continues to be one of the most promising clinical trials for patients with advanced metastatic breast cancer who have exhausted standard treatment options. It is in the final stages of the PH3 trial. Now we wait. https://clinicaltrials.gov/study/NCT06072612?term=bria-imt&viewType=Card&rank=1&tab=study
0 · Reply
JediGreen
JediGreen Jul. 16 at 8:29 PM
$BCTX Renmark Virtual Non-Deal Roadshow: TSX - BCT | NASDAQ - BCTX (ID 2997) https://renmark-drupal.s3.amazonaws.com/vndr/briacell-therapeutics-corp/2026-06-25-11-00-00/index.html
0 · Reply
Kirubin
Kirubin Jul. 16 at 3:01 PM
$BCTX news for this POS is bad news
1 · Reply
MikeTechnician
MikeTechnician Jul. 16 at 2:29 PM
$BCTX expands its pivotal Phase 3 metastatic breast cancer trial with Sunnybrook as its first Canadian site. Another step forward for Bria-IMT as enrollment momentum builds. #Biotech #CancerResearch #Immunotherapy News: https://bit.ly/4aUowNn
1 · Reply
MikeTechnician
MikeTechnician Jul. 16 at 1:43 PM
$BCTX continues to expand pivotal Phase 3 Bria-IMT study in metastatic breast cancer, with Sunnybrook’s Odette Cancer Centre now its first Canadian clinical site. Trial now includes 80+ active sites across 15 U.S. states and Canada. #Biotech #Cancer News: https://bit.ly/4aUowNn
0 · Reply
prismmarketview
prismmarketview Jul. 16 at 11:49 AM
BriaCell Therapeutics (NASDAQ: $BCTX) just opened its first Canadian site at Sunnybrook in Toronto for its pivotal Phase 3 Bria‑IMT™ trial in metastatic breast cancer, adding to a growing network of North American centers running a Fast Track‑designated study that could support full approval if survival data stay positive. https://prismmarketview.com/companies/briacell-therapeutics-corp/#news
1 · Reply
MarkeTimer
MarkeTimer Jul. 16 at 11:42 AM
$BCTX Tomorrows press release: bad dental hygiene causes cavities.
0 · Reply
STACKD0E
STACKD0E Jul. 16 at 11:41 AM
$MDCX $BCTX $DRIO ✨️
0 · Reply
SmallCapVoice
SmallCapVoice Jul. 16 at 11:33 AM
$BCTX BriaCell opened its first Canadian site at Sunnybrook’s Odette Cancer Centre for its pivotal Phase 3 metastatic breast cancer trial, expanding access to Bria-IMT as the study gains momentum and is featured in Nature Medicine as one of “Eleven clinical trials that will shape medicine in 2026.” https://www.globenewswire.com/news-release/2026/07/16/3328357/0/en/briacell-opens-first-canadian-site-sunnybrook-for-pivotal-phase-3-trial-in-metastatic-breast-cancer.html
0 · Reply
letsdodiz
letsdodiz Jul. 16 at 2:02 AM
$BCTX Briacell management has been a low effort team in the last 2-3 years. So to come up with these commercialization PRs l means something. It’s great to see these news while we wait.
1 · Reply
_gatti_
_gatti_ Jul. 15 at 8:52 PM
$BCTX market is sleeping on this. I guess people will buy when this is over $5 . I would like to see some institution buying based on the commercialization news
1 · Reply